Kyverna Therapeutics, Inc.·4

Feb 19, 5:55 PM ET

Shaw Christi 4

4 · Kyverna Therapeutics, Inc. · Filed Feb 19, 2025

Insider Transaction Report

Form 4
Period: 2025-02-14
Shaw Christi
DirectorExecutive Chairperson
Transactions
  • Award

    Stock Option (right to buy)

    2025-02-14+38,67938,679 total
    Exercise: $3.03Exp: 2035-02-14Common Stock (38,679 underlying)
Footnotes (1)
  • [F1]100% of the shares subject to the option shall be fully vested and exercisable on October 30, 2025, subject to the Reporting Person's continuous service to the Issuer as an advisor on and through the vesting date, inclusive.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4